Daiza Gordon watched her two younger brothers die from Hunter syndrome, a rare and incurable genetic disorder that mostly affects boys. It occurs when the body is missing a crucial enzyme. At just 19 years old, Gordon tried to resuscitate her youngest brother and failed. Years later, all three of her sons were diagnosed with the same disease. By the time her two eldest turned two, symptoms began to appear—thickened facial features, fading language skills, and physical decline.
This time, however, hope exists. As reported in Nature, Gordon’s sons are participating in a clinical trial testing a new kind of therapy that delivers the missing enzyme, iduronate-2-sulfatase (IDS), directly into the brain. This is a major breakthrough because IDS is too large to cross the blood–brain barrier on its own. Traditionally, treatments for Hunter syndrome have only protected other organs like the liver and kidneys, not the brain.
Now, scientists have developed a solution: a molecular “shuttle” that attaches to IDS and helps it pass through the brain’s protective barrier by mimicking the way natural nutrients like iron get in. Gordon’s sons have shown encouraging progress. Her eldest boys, once deaf, can now hear again and are physically active. Her youngest, who began treatment at just three months old, shows no signs of the disease. “When I look at them, I realize they have a chance of an actual future,” she told Nature.
The technique behind these brain shuttles is not just being explored for rare diseases like Hunter syndrome. It has the potential to revolutionize treatment for common brain conditions such as Alzheimer’s, Parkinson’s, and even brain cancer. The challenge lies in finding the right shuttle for each disease and ensuring it delivers its therapeutic cargo to the exact part of the brain that needs it. As one expert told Nature, nearly every major pharmaceutical company is now developing brain shuttle technologies.
These systems are already making an impact. In one Alzheimer’s trial, a drug linked to a shuttle cleared brain plaques much faster and at lower doses than its non-shuttled version, while reducing side effects. Researchers are also adapting this approach to carry advanced therapies like gene editing tools and RNA treatments into the brain. Some efforts involve engineering viruses to deliver healthy genes or using natural cell vesicles called exosomes to carry CRISPR components.
This shift in strategy marks a turning point in brain medicine. After years of slow progress and failed trials, pharmaceutical companies are investing again, often acquiring smaller biotech firms working on brain-targeted therapies. Between 2018 and 2023, shuttle technologies helped expand the pipeline of drugs for brain diseases by over 30%, with a growing share focused on large biological molecules—precisely the kind that need help crossing into the brain.
For families like Gordon’s, the science offers a powerful mix of realism and hope. The treatments are still experimental, and outcomes remain uncertain. But Gordon is holding onto the possibility of more time and better futures for her sons. As she told Nature, “I’m mentally prepared to see my boys decline — but optimistic that we will have a longer future together.”
